The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1451
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
The full article is available to subscribers Subscriber Login   

The FDA has approved vedolizumab (Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri), another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.1

STANDARD TREATMENT — Ulcerative Colitis – An aminosalicylate such as mesalamine is generally used first for induction and maintenance of remission in mild to moderate disease. An immunomodulator such as azathioprine or mercaptopurine is often used for maintenance of remission in patients with moderate to severe disease. Oral corticosteroids are effective for inducing remission in patients with moderate disease refractory to other drugs or in those ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Vedolizumab (Entyvio) for Inflammatory Bowel Disease
Article code: 1451b
 Electronic, downloadable article - $25